DexCom makes medical sensors that track blood sugar in real time for people with diabetes, allowing them to manage their health without constant finger-prick tests. The company generated $4.66 billion in revenue last year, and its most recent quarter showed 15% growth as it expanded further into international markets. After a period of transition, it is now shifting from a specialized tool for insulin users to a broader health wearable business.
The investment thesis on DexCom is that its new Stelo sensor transforms the company from a medical device provider for a niche group into a mass-market health technology platform for millions of non-insulin users. By expanding its reach beyond the traditional patient base, DexCom is opening a massive second front that competitors have yet to fully penetrate. If it can maintain its premium pricing while fending off cheaper rivals, its high-margin recurring revenue model will continue to scale.
We think the current stock price does not reflect the long-term value of a business that is finally turning its premium technology into a mass-market health platform. The move into non-insulin wearables is the most significant change in the company's history and should drive years of steady growth.
DexCom stock fell significantly over the last few years and has spent much of the recent time stuck. The price dropped as the company shifted away from serving only a small group of patients who use insulin. Lately, the shares have recovered a bit as the business creates sensors for millions of other people.
What does it do?
DexCom is a growth business that earns money by selling continuous glucose monitoring (CGM) systems that replace traditional blood sugar tests. The core mechanism involves a small sensor worn on the body that transmits blood sugar data to a smartphone or receiver every few minutes. Customers pay for the hardware (transmitters and receivers) and buy replacement sensors on a recurring basis, usually every 10 to 15 days. This recurring revenue model creates a steady stream of income as patients become reliant on the real-time data to manage their health.
Where does revenue come from?
The vast majority of revenue comes from selling sensors and transmitters through a global network of distributors. Distributors accounted for $1.01 billion of the $1.19 billion in revenue in the most recent quarter, while direct sales to clinics and patients made up the rest. Geographically, the United States is the primary market, contributing $832 million in the first quarter of 2026, though international revenue is growing faster at a 26% rate.
Revenue by Geography
Who are its customers?
DexCom serves millions of people with diabetes and healthcare providers who use its data to monitor patients. In the first quarter of 2026, the company generated $1.19 billion in revenue from its total user base, with international sales becoming a larger part of the mix. While specific patient counts are not disclosed every quarter, the company's growth to $5.2 billion in annual guided revenue for 2026 reflects a massive expansion in users across both the pharmacy and durable medical equipment channels. The recent launch of the Stelo sensor for non-insulin users has significantly expanded the potential customer pool beyond the traditional type 1 and intensive type 2 diabetes markets.
What gives it staying power?
DexCom has staying power because its sensors are deeply integrated into the medical ecosystem, making it very difficult for patients or doctors to switch. The company's technology is often "locked in" through software that connects directly to insulin pumps and physician monitoring platforms.
Where is it headed?
The company is headed toward becoming a general health wearable business through its new Stelo platform for non-insulin users. Management is betting that millions of people will pay for real-time metabolic data to improve their diet and exercise, even if they do not have advanced diabetes. This move shifts DexCom from a medical necessity to a preventative health tool.
Revenue growth is stabilizing after a period of reorganization, with 15% year-over-year growth in the most recent quarter. This trend is supported by a 26% jump in international sales, which is compensating for more moderate growth in the mature U.S. market. The company is now guiding for $5.16 billion to $5.25 billion in total revenue for 2026.
Cash generation is excellent, with free cash flow reaching $1.08 billion last year as the business scaled. This represents high-quality earnings, as free cash flow has consistently grown alongside net income over the past three years. The company currently holds $2.42 billion in cash and marketable securities, giving it plenty of room to fund its expansion.
The balance sheet is very strong, with the company holding enough cash to nearly double its total debt load of $1.24 billion. This net cash position is unusual for a growth-stage medical tech company and provides a significant safety net. It allows the company to invest heavily in new products like Stelo without needing to tap the capital markets.
DexCom is a financially healthy business that is successfully transitioning toward higher profitability while maintaining double-digit growth.
Operating margins expanded by 850 basis points to 21.4% in the most recent quarter due to lower manufacturing costs for the G7 sensor. The company is finding significant efficiency as it automates production, which allows profit to grow much faster than revenue.
A primary risk is the pricing pressure in the U.S. market as competitors like Abbott release cheaper versions of their sensors. If DexCom is forced to lower its prices to keep users, it could offset the gains it is making from manufacturing efficiencies.
The global continuous glucose monitoring market is roughly $10 billion today and is on track to exceed $16 billion by 2029 as it expands into the non-insulin market. This is an attractive industry because revenue is highly recurring and clinical evidence makes these devices a medical necessity for millions. Pricing power is generally strong due to high barriers to entry, though it is becoming more competitive as products move into the pharmacy channel. DexCom is a premium leader that sets the technical standard for the rest of the industry.
The competitive dynamic is rationally structured between two dominant players, but it is moving from a battle over technology to a battle over distribution. High barriers to entry prevent new startups from entering, while the complex regulatory path for medical devices protects the incumbents. Long-term pricing power depends on maintaining a clear technical advantage over cheaper alternatives.
Abbott is the primary threat, using its massive scale to offer lower prices and win in the broader type 2 diabetes market. Medtronic competes by bundling sensors with its own pumps, though its technology has historically lagged behind. Abbott’s Libre line is the most dangerous threat because its lower price point appeals to insurance companies looking to control costs.
DexCom is holding ground in the premium segment while successfully expanding into the non-insulin market with Stelo. The 15% revenue growth in the latest quarter proves it can still win share despite intense competition.
The primary protection comes from high switching costs and the deep integration of DexCom data into the physician's workflow. Once a patient is trained on the software and a doctor is set up to receive the data, the friction of moving to a rival system is high. DexCom’s 18% ROIC proves it can earn returns well above its cost of capital.
The combination of 62% gross margins and high customer retention numbers proves this is a durable advantage rather than a temporary trend. These numbers are consistent with a real moat that allows the company to maintain premium pricing even as competitors launch cheaper products. The consistent profitability through different product cycles validates the strength of the business model.
The moat is strengthening as the company moves from a medical device to a data-driven health platform. The expansion into non-insulin users creates a massive new pool of proprietary data that competitors cannot easily replicate.
Met or beat revenue guidance for the last four quarters while expanding margins.
Used cash to expand G7 production capacity while maintaining a $2.42B cash balance.
CEO stake is modest, but pay is tied to long-term operational targets.
Capital Allocation Track Record
Management is led by Jacob Steven Leach, who has successfully steered the company through the transition from the G6 to the higher-margin G7 sensor. The leadership team has shown strong judgment by moving into the non-insulin market early, positioning the company to capture a massive new audience before competitors could react. Their ability to expand operating margins by 850 basis points in a single year proves they are capable operators who can turn revenue growth into real profit.
Leadership continuity risk is low as the company has a deep bench of executives and a well-established strategic plan. While the thesis is not overly dependent on any single individual, the company's culture of innovation is its most valuable intangible asset. The primary governance factor is the board's focus on maintaining high R&D spending, which ensures the company stays ahead of larger rivals like Abbott.
We expect revenue to grow from $5.2B in FY2026 to $9.2B in FY2031 (~12% CAGR), with EPS growing from $2.59 to $5.85 (~18% CAGR). The new Stelo sensor is expanding the market to millions of non-insulin users who previously did not use continuous monitoring. Automated production of the G7 sensor reduces the labor cost for every unit sold as the company scales. EPS grows faster than revenue because profit margins are widening Operating margin expected to reach ~28% by FY2031.
Stelo sensor scales into the mass-market metabolic health segment. If millions of non-insulin users adopt CGM for general health, DexCom’s total addressable market triples in size.
Automated G7 production drives gross margins above 65%. Moving manufacturing from manual labor to fully automated lines permanently lowers the cost of every sensor sold.
International expansion in the pharmacy channel accelerates growth. Winning more reimbursement in European and Asian markets allows DexCom to tap into large, underserved patient populations.
Price compression in the U.S. pharmacy channel hurts revenue. If insurance companies force DexCom to match Abbott’s lower prices, revenue growth could stall despite higher volumes.
Competitors launch sensors with longer wear times than G7. If a rival launches a 30-day sensor that is as accurate as DexCom, the company could lose its premium status.
GLP-1 drugs reduce the long-term need for glucose monitoring. While currently a tailwind, if weight-loss drugs effectively "cure" type 2 diabetes for some, the need for constant monitoring could drop.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to future earnings) as the primary valuation framework. It fits DexCom because the company has achieved consistent GAAP profitability and high recurring revenue from sensor replacements, making earnings a more reliable and mature signal of value than early-stage revenue multiples.
Applying a 35x multiple to the FY2027 EPS projection of $3.09 results in a per-share fair value of $108. This 35x multiple sits at the upper end of the medical device peer range (Abbott at 26x, Medtronic at 18x, Insulet at 38x), a premium we believe is justified by DexCom's superior revenue growth and its successful expansion into the over-the-counter market. We use the FY2027 EPS of $3.09 provided by the deterministic projection engine to ensure consistency with the broader report’s fundamental outlook.
Cross-checked with an EV/Revenue framework (FY2027 estimated revenue of $6.1B × 7.0x peer-anchored multiple), we arrive at a fair value of $110 per share. This result is within 2% of our primary Forward P/E answer of $108, providing high confidence in the valuation. The 7.0x revenue multiple is consistent with high-margin medical technology leaders and accounts for the company's 60%+ gross margin profile. These two independent frameworks strongly agree, suggesting the $108–$110 range accurately reflects the company's intrinsic value.
We're assuming the Stelo OTC glucose sensor achieves significant adoption among the 25 million non-insulin using Type 2 diabetics in the U.S. This platform is a fundamental shift for DexCom, moving from a prescribed medical necessity to a proactive wellness tool, supported by the $100 million in revenue generated during its first twelve months on the market.
We're assuming DexCom maintains its "premium" pricing tier despite broader competition in the CGM space. The business has historically successfully defended its price point through superior interoperability with insulin pumps like Tandem and Insulet, and recent FDA clearances for pediatric use further solidify this high-moat clinical positioning.
We're assuming net profit margins expand from current levels toward 22% by FY2027 as production scales. The G7 sensor is significantly smaller and more automated to manufacture than the previous G6 model, which should allow DexCom to grow earnings faster than revenue as fixed costs are distributed over a larger volume of sensors.
The biggest risk is aggressive pricing competition from Abbott’s FreeStyle Libre 3, which could force DexCom to trade accuracy for lower price points. A sustained price war that compresses sensor average selling prices by 15% would likely knock the forward multiple from 35x to 22x, reducing the fair value by approximately $40 per share. Watch for any sequential decline in gross margins in the upcoming Q2 and Q3 prints as the primary signal of this pricing pressure.
Bear case ($68): Gross margins drop below 58% as Abbott’s FreeStyle Libre 3 pricing forces a permanent industry-wide ASP reset; or Stelo quarterly revenue contribution fails to reach $50M by Q4 FY2026, suggesting the non-insulin market is harder to penetrate than modeled.
Bull case ($136): International revenue growth accelerates above 25% following the G7 rollout in secondary European and Asian markets; or Operating leverage from automated G7 manufacturing lines pushes net margins toward 25% by FY2027, ahead of the current 19% trajectory.
Clearthesis wrote this report from 38 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is bullish because Dexcom is successfully expanding its sensor technology from a niche medical tool into a mass-market wearable for millions of non-insulin users. Recent studies prove that its glucose monitors significantly improve health outcomes for the much larger population of Type 2 diabetics not using insulin, effectively widening the company's total addressable customer base.
Skeptics think that operational mismanagement and inventory issues could damage the company's reputation as it tries to scale up. Reports that sensors slated for destruction were found in the supply chain raise serious questions about the company's internal control processes as they pivot toward high-volume consumer distribution.